You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIproniazid
Accession NumberDB04818
TypeSmall Molecule
GroupsWithdrawn
DescriptionWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EuphozidNot Available
IprazidNot Available
IpronidA.F.I.
IproninNot Available
MarsilidGenopharm
RivivolZambeletti
Brand mixturesNot Available
SaltsNot Available
Categories
UNIID892HFI3XA
CAS number54-92-2
WeightAverage: 179.219
Monoisotopic: 179.105862053
Chemical FormulaC9H13N3O
InChI KeyInChIKey=NYMGNSNKLVNMIA-UHFFFAOYSA-N
InChI
InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)
IUPAC Name
N'-(propan-2-yl)pyridine-4-carbohydrazide
SMILES
CC(C)NNC(=O)C1=CC=NC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPyridinecarboxylic acids and derivatives
Direct ParentPyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Pyridine carboxylic acid or derivatives
  • Heteroaromatic compound
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression (originally intended to treat tuberculosis).
PharmacodynamicsIproniazid is a monoamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant.
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9929
Blood Brain Barrier+0.9799
Caco-2 permeable+0.6657
P-glycoprotein substrateNon-substrate0.7484
P-glycoprotein inhibitor INon-inhibitor0.9191
P-glycoprotein inhibitor IINon-inhibitor0.9932
Renal organic cation transporterNon-inhibitor0.9166
CYP450 2C9 substrateNon-substrate0.8608
CYP450 2D6 substrateNon-substrate0.873
CYP450 3A4 substrateNon-substrate0.614
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9316
CYP450 2D6 inhibitorNon-inhibitor0.9522
CYP450 2C19 inhibitorNon-inhibitor0.9293
CYP450 3A4 inhibitorNon-inhibitor0.7165
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9221
Ames testNon AMES toxic0.5653
CarcinogenicityNon-carcinogens0.7081
BiodegradationNot ready biodegradable0.9893
Rat acute toxicity2.6600 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.943
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point161-161.5U.S. Patent 2,685,585.
logP0.37HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.674 mg/mLALOGPS
logP0.02ALOGPS
logP0.31ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)13.66ChemAxon
pKa (Strongest Basic)3.82ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area54.02 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity60.96 m3·mol-1ChemAxon
Polarizability19.19 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

U.S. Patent 2,685,585.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineIproniazid may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineIproniazid may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
AcarboseIproniazid may increase the hypoglycemic activities of Acarbose.
AcebutololIproniazid may increase the hypotensive activities of Acebutolol.
AlbiglutideIproniazid may increase the hypoglycemic activities of Albiglutide.
AliskirenIproniazid may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Iproniazid.
AlogliptinIproniazid may increase the hypoglycemic activities of Alogliptin.
AlprenololIproniazid may increase the hypotensive activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Iproniazid.
AmbrisentanIproniazid may increase the hypotensive activities of Ambrisentan.
AmineptineIproniazid may increase the serotonergic activities of Amineptine.
AmitriptylineIproniazid may increase the serotonergic activities of Amitriptyline.
AmlodipineIproniazid may increase the hypotensive activities of Amlodipine.
AmoxapineIproniazid may increase the serotonergic activities of Amoxapine.
AmphetamineIproniazid may increase the hypertensive activities of Amphetamine.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Iproniazid.
ApraclonidineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Apraclonidine.
ArbutamineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Arformoterol.
AtenololIproniazid may increase the hypotensive activities of Atenolol.
AtomoxetineIproniazid may increase the central neurotoxic activities of Atomoxetine.
AtropineIproniazid may increase the hypertensive activities of Atropine.
BambuterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Bambuterol.
BenazeprilIproniazid may increase the hypotensive activities of Benazepril.
BendroflumethiazideIproniazid may increase the hypotensive activities of Bendroflumethiazide.
BenzphetamineIproniazid may increase the hypertensive activities of Benzphetamine.
BepridilIproniazid may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Iproniazid.
BetaxololIproniazid may increase the hypotensive activities of Betaxolol.
BethanidineIproniazid may increase the hypotensive activities of Bethanidine.
BezafibrateThe risk or severity of adverse effects can be increased when Iproniazid is combined with Bezafibrate.
BimatoprostIproniazid may increase the hypotensive activities of Bimatoprost.
BisoprololIproniazid may increase the hypotensive activities of Bisoprolol.
BosentanIproniazid may increase the hypotensive activities of Bosentan.
BretyliumIproniazid may increase the hypotensive activities of Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Brimonidine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Iproniazid.
BupranololIproniazid may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproniazid.
BupropionIproniazid may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Iproniazid.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Iproniazid.
CanagliflozinIproniazid may increase the hypoglycemic activities of Canagliflozin.
CandesartanIproniazid may increase the hypotensive activities of Candesartan.
CandoxatrilIproniazid may increase the hypotensive activities of Candoxatril.
CaptoprilIproniazid may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iproniazid.
CarteololIproniazid may increase the hypotensive activities of Carteolol.
CarvedilolIproniazid may increase the hypotensive activities of Carvedilol.
CeliprololIproniazid may increase the hypotensive activities of Celiprolol.
ChlorothiazideIproniazid may increase the hypotensive activities of Chlorothiazide.
ChlorphentermineIproniazid may increase the hypertensive activities of Chlorphentermine.
ChlorpropamideIproniazid may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneIproniazid may increase the hypotensive activities of Chlorthalidone.
CilazaprilIproniazid may increase the hypotensive activities of Cilazapril.
CirazolineIproniazid may increase the hypertensive activities of Cirazoline.
CitalopramIproniazid may increase the serotonergic activities of Citalopram.
ClemastineIproniazid may increase the anticholinergic activities of Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Clenbuterol.
ClomipramineIproniazid may increase the serotonergic activities of Clomipramine.
ClonidineIproniazid may increase the hypotensive activities of Clonidine.
CryptenamineIproniazid may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Iproniazid.
CyclothiazideIproniazid may increase the hypotensive activities of Cyclothiazide.
CyproheptadineIproniazid may increase the anticholinergic activities of Cyproheptadine.
DapagliflozinIproniazid may increase the hypoglycemic activities of Dapagliflozin.
DapoxetineIproniazid may increase the serotonergic activities of Dapoxetine.
DebrisoquinIproniazid may increase the hypotensive activities of Debrisoquin.
DeserpidineIproniazid may increase the hypotensive activities of Deserpidine.
DesipramineIproniazid may increase the serotonergic activities of Desipramine.
DesvenlafaxineIproniazid may increase the serotonergic activities of Desvenlafaxine.
DexmethylphenidateIproniazid may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineIproniazid may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanIproniazid may increase the serotonergic activities of Dextromethorphan.
DiazoxideIproniazid may increase the hypotensive activities of Diazoxide.
DiethylpropionIproniazid may increase the hypertensive activities of Diethylpropion.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Iproniazid.
DiltiazemIproniazid may increase the hypotensive activities of Diltiazem.
DipivefrinThe risk or severity of adverse effects can be increased when Iproniazid is combined with Dipivefrin.
DisopyramideIproniazid may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Dobutamine.
DomperidoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Domperidone.
DorzolamideIproniazid may increase the hypotensive activities of Dorzolamide.
DosulepinIproniazid may increase the serotonergic activities of Dosulepin.
DoxapramIproniazid may increase the hypertensive activities of Doxapram.
DoxazosinIproniazid may increase the hypotensive activities of Doxazosin.
DoxepinIproniazid may increase the serotonergic activities of Doxepin.
DoxylamineIproniazid may increase the anticholinergic activities of Doxylamine.
DroxidopaThe risk or severity of adverse effects can be increased when Iproniazid is combined with Droxidopa.
DulaglutideIproniazid may increase the hypoglycemic activities of Dulaglutide.
DuloxetineIproniazid may increase the serotonergic activities of Duloxetine.
EfonidipineIproniazid may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Iproniazid.
EmpagliflozinIproniazid may increase the hypoglycemic activities of Empagliflozin.
EnalaprilIproniazid may increase the hypotensive activities of Enalapril.
EnalaprilatIproniazid may increase the hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Iproniazid.
EphedraThe risk or severity of adverse effects can be increased when Iproniazid is combined with Ephedra.
EpinephrineIproniazid may increase the hypertensive activities of Epinephrine.
EpoprostenolIproniazid may increase the hypotensive activities of Epoprostenol.
EprosartanIproniazid may increase the hypotensive activities of Eprosartan.
ErgotamineIproniazid may increase the hypertensive activities of Ergotamine.
EscitalopramIproniazid may increase the serotonergic activities of Escitalopram.
EsmirtazapineIproniazid may increase the serotonergic activities of Esmirtazapine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Iproniazid.
EtoperidoneIproniazid may increase the serotonergic activities of Etoperidone.
ExenatideIproniazid may increase the hypoglycemic activities of Exenatide.
FelodipineIproniazid may increase the hypotensive activities of Felodipine.
FenfluramineIproniazid may increase the serotonergic activities of Fenfluramine.
FenoldopamIproniazid may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Fenoterol.
FluoxetineIproniazid may increase the serotonergic activities of Fluoxetine.
FluvoxamineIproniazid may increase the serotonergic activities of Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Formoterol.
FosinoprilIproniazid may increase the hypotensive activities of Fosinopril.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Iproniazid.
GliclazideIproniazid may increase the hypoglycemic activities of Gliclazide.
GlimepirideIproniazid may increase the hypoglycemic activities of Glimepiride.
GlipizideIproniazid may increase the hypoglycemic activities of Glipizide.
GlyburideIproniazid may increase the hypoglycemic activities of Glyburide.
GuanabenzIproniazid may increase the hypotensive activities of Guanabenz.
GuanadrelIproniazid may increase the hypotensive activities of Guanadrel.
GuanethidineIproniazid may increase the hypotensive activities of Guanethidine.
GuanfacineIproniazid may increase the hypotensive activities of Guanfacine.
HexamethoniumIproniazid may increase the hypotensive activities of Hexamethonium.
HydralazineIproniazid may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideIproniazid may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydrocodone.
HydroflumethiazideIproniazid may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideIproniazid may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
ImipramineIproniazid may increase the serotonergic activities of Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Indacaterol.
IndalpineIproniazid may increase the serotonergic activities of Indalpine.
IndapamideIproniazid may increase the hypotensive activities of Indapamide.
IndenololIproniazid may increase the hypotensive activities of Indenolol.
IndoraminIproniazid may increase the hypotensive activities of Indoramin.
Insulin AspartIproniazid may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirIproniazid may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineIproniazid may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineIproniazid may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanIproniazid may increase the hypoglycemic activities of Insulin Human.
Insulin LisproIproniazid may increase the hypoglycemic activities of Insulin Lispro.
IrbesartanIproniazid may increase the hypotensive activities of Irbesartan.
IsoetarineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isoetarine.
IsomethepteneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Isoprenaline.
IsradipineIproniazid may increase the hypotensive activities of Isradipine.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Iproniazid.
LabetalolIproniazid may increase the hypotensive activities of Labetalol.
LacidipineIproniazid may increase the hypotensive activities of Lacidipine.
LanreotideIproniazid may increase the hypoglycemic activities of Lanreotide.
LatanoprostIproniazid may increase the hypotensive activities of Latanoprost.
LercanidipineIproniazid may increase the hypotensive activities of Lercanidipine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Iproniazid.
LevomilnacipranIproniazid may increase the serotonergic activities of Levomilnacipran.
LevonordefrinIproniazid may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Linezolid.
LiraglutideIproniazid may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineIproniazid may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilIproniazid may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Iproniazid.
LithiumThe risk or severity of adverse effects can be increased when Iproniazid is combined with Lithium.
LofexidineIproniazid may increase the hypotensive activities of Lofexidine.
LosartanIproniazid may increase the hypotensive activities of Losartan.
Lu AA21004Iproniazid may increase the serotonergic activities of Lu AA21004.
MacitentanIproniazid may increase the hypotensive activities of Macitentan.
ManidipineIproniazid may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Iproniazid.
MecamylamineIproniazid may increase the hypotensive activities of Mecamylamine.
MecaserminIproniazid may increase the hypoglycemic activities of Mecasermin.
MephentermineIproniazid may increase the hypertensive activities of Mephentermine.
MequitazineIproniazid may increase the anticholinergic activities of Mequitazine.
MetaraminolIproniazid may increase the hypertensive activities of Metaraminol.
MetforminIproniazid may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Methadone.
MethamphetamineIproniazid may increase the hypertensive activities of Methamphetamine.
MethoxamineIproniazid may increase the hypertensive activities of Methoxamine.
MethyldopaThe risk or severity of adverse effects can be increased when Iproniazid is combined with Methyldopa.
Methylene blueIproniazid may increase the serotonergic activities of Methylene blue.
MethylphenidateIproniazid may increase the hypertensive activities of Methylphenidate.
MetipranololIproniazid may increase the hypotensive activities of Metipranolol.
MetolazoneIproniazid may increase the hypotensive activities of Metolazone.
MetoprololIproniazid may increase the hypotensive activities of Metoprolol.
MianserinIproniazid may increase the neurotoxic activities of Mianserin.
MibefradilIproniazid may increase the hypotensive activities of Mibefradil.
MidodrineIproniazid may increase the hypertensive activities of Midodrine.
MifepristoneIproniazid may increase the hypoglycemic activities of Mifepristone.
MiglitolIproniazid may increase the hypoglycemic activities of Miglitol.
MilnacipranIproniazid may increase the serotonergic activities of Milnacipran.
MinoxidilIproniazid may increase the hypotensive activities of Minoxidil.
MirtazapineIproniazid may increase the central neurotoxic activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Iproniazid is combined with Moclobemide.
MoexiprilIproniazid may increase the hypotensive activities of Moexipril.
MorphineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Morphine.
MoxonidineIproniazid may increase the hypotensive activities of Moxonidine.
NadololIproniazid may increase the hypotensive activities of Nadolol.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Iproniazid.
NateglinideIproniazid may increase the hypoglycemic activities of Nateglinide.
NebivololIproniazid may increase the hypotensive activities of Nebivolol.
NicardipineIproniazid may increase the hypotensive activities of Nicardipine.
NicorandilIproniazid may increase the hypotensive activities of Nicorandil.
NiguldipineIproniazid may increase the hypotensive activities of Niguldipine.
NilvadipineIproniazid may increase the hypotensive activities of Nilvadipine.
NimodipineIproniazid may increase the hypotensive activities of Nimodipine.
NisoldipineIproniazid may increase the hypotensive activities of Nisoldipine.
NitrendipineIproniazid may increase the hypotensive activities of Nitrendipine.
NitroprussideIproniazid may increase the hypotensive activities of Nitroprusside.
NorepinephrineIproniazid may increase the hypertensive activities of Norepinephrine.
NortriptylineIproniazid may increase the serotonergic activities of Nortriptyline.
OctreotideIproniazid may increase the hypoglycemic activities of Octreotide.
OlanzapineIproniazid may increase the serotonergic activities of Olanzapine.
OlmesartanIproniazid may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Olodaterol.
OmapatrilatIproniazid may increase the hypotensive activities of Omapatrilat.
OrciprenalineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Orciprenaline.
OxprenololIproniazid may increase the hypotensive activities of Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Iproniazid is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iproniazid.
PargylineIproniazid may increase the hypotensive activities of Pargyline.
ParoxetineIproniazid may increase the serotonergic activities of Paroxetine.
PasireotideIproniazid may increase the hypoglycemic activities of Pasireotide.
PenbutololIproniazid may increase the hypotensive activities of Penbutolol.
PentamidineIproniazid may increase the hypoglycemic activities of Pentamidine.
PentoliniumIproniazid may increase the hypotensive activities of Pentolinium.
PergolideThe metabolism of Pergolide can be decreased when combined with Iproniazid.
PerindoprilIproniazid may increase the hypotensive activities of Perindopril.
PethidineIproniazid may increase the serotonergic activities of Pethidine.
PhenoxybenzamineIproniazid may increase the hypotensive activities of Phenoxybenzamine.
PhentermineIproniazid may increase the hypertensive activities of Phentermine.
PhentolamineIproniazid may increase the hypotensive activities of Phentolamine.
PhenylephrineIproniazid may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Phenylpropanolamine.
PholcodinePholcodine may increase the serotonergic activities of Iproniazid.
PinacidilIproniazid may increase the hypotensive activities of Pinacidil.
PindololIproniazid may increase the hypotensive activities of Pindolol.
PioglitazoneIproniazid may increase the hypoglycemic activities of Pioglitazone.
PirbuterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Pirbuterol.
PizotifenIproniazid may increase the anticholinergic activities of Pizotifen.
PolythiazideIproniazid may increase the hypotensive activities of Polythiazide.
PramlintideIproniazid may increase the hypoglycemic activities of Pramlintide.
PrazosinIproniazid may increase the hypotensive activities of Prazosin.
ProcaterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Procaterol.
PropranololIproniazid may increase the hypotensive activities of Propranolol.
ProtriptylineIproniazid may increase the serotonergic activities of Protriptyline.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Iproniazid.
QuinaprilIproniazid may increase the hypotensive activities of Quinapril.
QuinineIproniazid may increase the hypoglycemic activities of Quinine.
RamiprilIproniazid may increase the hypotensive activities of Ramipril.
RemikirenIproniazid may increase the hypotensive activities of Remikiren.
RepaglinideIproniazid may increase the hypoglycemic activities of Repaglinide.
RescinnamineIproniazid may increase the hypotensive activities of Rescinnamine.
ReserpineIproniazid may increase the hypotensive activities of Reserpine.
RiociguatIproniazid may increase the hypotensive activities of Riociguat.
RitodrineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Ritodrine.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Iproniazid.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Iproniazid.
RosiglitazoneIproniazid may increase the hypoglycemic activities of Rosiglitazone.
SalbutamolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salmeterol.
SaprisartanIproniazid may increase the hypotensive activities of Saprisartan.
SaxagliptinIproniazid may increase the hypoglycemic activities of Saxagliptin.
SelexipagIproniazid may increase the hypotensive activities of Selexipag.
SertralineIproniazid may increase the serotonergic activities of Sertraline.
SitagliptinIproniazid may increase the hypoglycemic activities of Sitagliptin.
SitaxentanIproniazid may increase the hypotensive activities of Sitaxentan.
SpiraprilIproniazid may increase the hypotensive activities of Spirapril.
SulfadiazineIproniazid may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleIproniazid may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleIproniazid may increase the hypoglycemic activities of Sulfisoxazole.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Iproniazid.
SunitinibIproniazid may increase the hypoglycemic activities of Sunitinib.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Iproniazid.
TelmisartanIproniazid may increase the hypotensive activities of Telmisartan.
TemocaprilIproniazid may increase the hypotensive activities of Temocapril.
TerbutalineThe risk or severity of adverse effects can be increased when Iproniazid is combined with Terbutaline.
TerlipressinIproniazid may increase the hypotensive activities of Terlipressin.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Iproniazid.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iproniazid.
TetryzolineIproniazid may increase the hypertensive activities of Tetryzoline.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Iproniazid.
TianeptineIproniazid may increase the serotonergic activities of Tianeptine.
TiboloneIproniazid may increase the hypotensive activities of Tibolone.
TicrynafenIproniazid may increase the hypotensive activities of Ticrynafen.
TimololIproniazid may increase the hypotensive activities of Timolol.
TolazamideIproniazid may increase the hypoglycemic activities of Tolazamide.
TolazolineIproniazid may increase the hypotensive activities of Tolazoline.
TolbutamideIproniazid may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iproniazid.
TorasemideIproniazid may increase the hypotensive activities of Torasemide.
TramadolTramadol may increase the neuroexcitatory activities of Iproniazid.
TrandolaprilIproniazid may increase the hypotensive activities of Trandolapril.
TravoprostIproniazid may increase the hypotensive activities of Travoprost.
TrazodoneIproniazid may increase the serotonergic activities of Trazodone.
TreprostinilIproniazid may increase the hypotensive activities of Treprostinil.
TrichlormethiazideIproniazid may increase the hypotensive activities of Trichlormethiazide.
TrimazosinIproniazid may increase the hypotensive activities of Trimazosin.
TrimethaphanIproniazid may increase the hypotensive activities of Trimethaphan.
TrimipramineIproniazid may increase the serotonergic activities of Trimipramine.
UnoprostoneIproniazid may increase the hypotensive activities of Unoprostone.
ValsartanIproniazid may increase the hypotensive activities of Valsartan.
VenlafaxineIproniazid may increase the serotonergic activities of Venlafaxine.
VilanterolThe risk or severity of adverse effects can be increased when Iproniazid is combined with Vilanterol.
VilazodoneIproniazid may increase the serotonergic activities of Vilazodone.
VortioxetineIproniazid may increase the serotonergic activities of Vortioxetine.
XylometazolineIproniazid may increase the hypotensive activities of Xylometazoline.
ZimelidineIproniazid may increase the serotonergic activities of Zimelidine.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Iproniazid.
Food InteractionsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
Comments
comments powered by Disqus
Drug created on September 11, 2007 14:12 / Updated on August 17, 2016 12:24